Amryt Pharma PLC

Receive alerts
Market Cap:
£67.51 m
52 weeks high
52 weeks low

Viewing results 1-25 of 232


Amryt soars as US bankruptcy court clears way for Aegerion acquisition

Orphan drug firm Amryt said it would acquire Aegerion once the approved plan of reorganisation came into effect on or around 24 September...

1 week, 3 days ago

Amryt Pharma provides detail of Aegerion deal

The group outlined the mechanics of the transformational transaction ...

3 weeks, 4 days ago

Open Orphan starts trading on AIM

Open Orphan was co-founded back in 2017 by Cathal Friel, the serial Irish investor behind companies such as Amryt Pharma and Fastnet...

on 06/28/2019

Venn Life Sciences launches £4.5mln share placing to fund life after reverse takeover

The cash will be used to bankroll and grow the enlarged group...

on 06/11/2019

Amryt Phama to take control of Lojuxta through merger with US firm Aegerion

Aegerion is a subsidiary of Nasdaq-listed Novelion Therapeutics and the way the deal has been structured values Amryt at US$120mln ...

on 05/21/2019

Open Orphan set to join AIM as it agrees reverse takeover of Venn Life Sciences

Open Orphan was co-founded back in 2017 by Cathal Friel, the serial Irish investor behind companies such as Amryt Pharma and Fastnet...

on 05/10/2019

Amryt Pharma creating the building blocks for commercial success

Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year...

on 04/17/2019

Amryt Pharma given permission to extend age eligibility for drug trial

Amryt is developing AP101 as a potential treatment for Epidermolysis Bullosa, where skin blisters to the touch...

on 02/28/2019

Amryt Pharma adds new element to promising portfolio

“If successful, this platform [AP103] has potential in other genetic skin conditions and beyond” ...

on 02/08/2019

Amryt Pharma says new cream delivers encouraging early results

AP103 is a putative treatment for recessive dystrophic epidermolysis bullosa, a severe and very difficult to treat skin condition...

on 01/07/2019

Amryt to add another 48 patients to Phase III trial of skin disorder cream

“The IDMC's recommendation is good news for Amryt as it allows us to continue the trial with only a modest increase in the size of the study”...

on 01/04/2019

Amryt Pharma opens the first US site for its global AP101 EASE Phase III clinical trial for rare skin condition

The AIM-listed company also said it has received notification that the Independent Data Monitoring Committee is scheduled to meet on 21 December to review the EASE data...

on 12/19/2018

Amryt Pharma receives €8.4mln from Irish government to develop treatment for rare skin condition

The grants will be paid out over the next three years and will fund the development of Amryt’s AP103 gene therapy platform, which has shown potential as a treatment for Recessive Dystrophic Epidermolysis Bullosa...

on 12/10/2018

Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available in France in early 2019

The approval from French regulators means Lojuxta will soon be available in all five of the EU’s largest markets...

on 10/17/2018

Amryt Pharma revenues rise in first half following jump in Lojuxta sales

The pharmaceutical firm reported a narrowed loss before tax of €11.3mln for the period, less than a €13.8mln loss a year ago, while revenues grew to €7mln from €6.1mln previously...

on 09/26/2018

Amryt to expand late-stage skin disorder trial into US after green light from FDA

Regulators have granted AP101 investigational new drug clearance, meaning the ongoing phase III worldwide trial can now be expanded into the US...

on 09/10/2018

Amryt Pharma skin treatment given special designation by US regulator

Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch...

on 08/02/2018

Amryt Pharma making strong progress with momentum continuing to build

The company is a rarity among the junior drug companies because it has a successful and revenue generating product out on the market and a promising drug in the final stages of clinical development ...

on 07/19/2018

Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available on NHS

The drug developer expects its top line to benefit from the decision from 2019 and beyond...

on 07/09/2018

Amryt signs four Middle East distribution agreements for its cholesterol treatment, Lojuxta

The incidence of homozygous familial hypercholesterolaemia, the rare cholesterol disorder treated by Lojuxta, is higher in the Middle East than it is in Europe...

on 05/29/2018